REGISTERED CHARITY NUMBER: 3272116
Tru5tees' Re￿rt attd
Audited FinAD¢fjal Ststements for the Year Ended 31 De¢ember 2025
for
Drug Safety Researeh Trn$t

Dru¥ Safety Research Trust
Cont¢nts of the Finan¢lal Statements
for the Year Ended 31 Deeember 2025
Page
Reference and Admithlstrntlve Details
Trustees. Report
State￿¢￿t of Tru5tee5' Responslbllltl¢$
10
Rewbrt of tbe IndependeAt Audltors
11 to 14
Statement of Flnancl#l Actlvltles
15
Statemertt of Firtaneial Position
16
Statement of Cash FIDY4$
17
Notes to the Si*tement of Cash Flows
18
Notes to the Flnan¢lal state￿ents
19 to 29
Detalled Statement of Flnanelal AetR)4ties
30 to 31

Drug Safety Research Trust
Reference and Admintstratlve Detsiis
for the Yexr Ended 31 December 2025
TRUSTEES
Prof¢55or Kenneth Ross Paterson MB ChB FRCP FFPM FBPhS (Chainnalll
Prof¢550r John Can1￿ QHP BS¢ MD FRCP FESC FACC FAHA FCGC CStJ
Profe550r Martin Ves5¢y CBE MD FRCP FRCOG FRCGP FFPH Fmcdsci FRS
Piofessor Allan Hunter Young MB, ChB, MPhil, PhD, FRCPC, FRCPsych
PTofe5sor Isla Ma¢kenzie MB ChB PhD PGC¢rtMcdEd FRCP Edin FBPhS FBIHS
DIRECTOR
Dr Linda Harllwk M.Pharn4 M.Epi. Ph¢L MBA lappoillted 22 April 20251
PRINCIPAL ADDRESS
Drllg Safety Research Unit
Bur51edon Hall
Bur51edon Lane
Bur51edon
Southampton
S031 IAA
REGISTERED CHARrrY
NUMBER
327206
INDEPENDENT AUDITORS
Cartwrights
Chartered Accountants and Bu5ines5 Advisors
Statutory Auditor
Regency House
33 Wood Street
Barnet
Hertfordshire
EN5 4BE
PROFESSIONAL ADVISERS
Solicitors
Patis Smith LLP
Number l LonÉton Road
Southampton
S015 2AE
Jnv¢stment Managers
Rathbones lThvcstm¢nt Manage￿ent Limited
30 CJr¢%ham Strcet
London
EC2V 7QN
PRll¥CIPAL BANKERS
Lloyd5 Bank plc
92-94 Above Bar St
SouthaM￿On
S014 7DT

Drug Safety Research Trust
Tru$t¢e$' Report
for the Year Ended 31 December 2025
The Trnstees present their re￿}rt with tbe fillancial sratements of the ckniry for the year ended 31 December 2025.
The Trustees have adopied the provisions of Accounting and Reporting by Charities.. Siatemellt of Recommendeij
Pracute applicable to charities preparing their accounts in accordance with the Financial Reponing Standard
applicable in the UK and Republic of Ireland (FRS 102) (effective l January 2019}.
Objeetives and aims
Established in 1981. the Drug Safety Research Unit IDSRUI mission is to protect public health by studying the use
alld adverse effects of medicines and vaccities in real-world clinical use, working to tbe highest possible seientifie
stattdardg. All of our work seeks to facilitate the healtb and wellbeing of p￿IentS by putting the interests of patients
first and protectitlg people from the hazards of medicines.
To achieve this mission. the DSRU ¢JtTer a range of observational studies to examine the safety of medicines, including
new medicioes. new fomiulalions for existing medicines and when medicines are used for new indications or in new
populations. or when safety issues or questions about the use, benefit-risk balance or effectiveness of medicines arise.
In addition. the unil conducts utilisation studies for medicines and vac¢ines ¢0 enable underStandi￿g the use and
effects of pr(Nluds on the healthcare system and behaviours and responses of patients and healthcare professionals.
The type of s￿dIeS offered include CPRD s￿dies, p)st-allthorisation s*f¢ty Studies (PASS) in primary and wondary
care, registries (including for the Early Access to Medicines Sehtme, EAMS), European network studies, $ystem2ti¢
reviews, drng uttli￿tion studies and benefjt-risk assessments. It also offers services with regards to the design and
implementation additional risk minimisation measures and to monitor their effectiveness.
In additio￿ DSRU Seeks to contribute to the advancement of phannacovigilanee 2nd phamwoepidemÈology by
conth]cting methodological research. leading or participating in natioTLa] aTLd international research network5 and
scientific collaborative projects and by orgalllSing meetings and eonferences to explore and develop new methods and
innovations in phaM￿Cov1s][a￿cC and pharnracoepidemiology.
DSRU Consultancy provides advice on strategies. thdy designs and options for post-marketittg pharnJacovigilan¢e.
pham)acoepidemiology. risk minimisatith) and risk management planning for large and small pharmaceutical
companies.
DSRU Educath"on & Training is
phamia¢oepidemiology and risk managemenL
leading European provider of training in
pharn)a¢ovigilan¢£,
OBJECTIVES AND ACTIVITIES
ObjeetÉves and aims
We continue to rnonitor developments in the UK relationship with the EU atLd make adjustments to our systems as
appropriate to adthess relevallt i55ues arising froln these changes.
The Director keeps in regular contact with the Regulatory Agencies #t￿ our European colleagues to obtain
infotmation in order io shape our strategy and policy, particularly on Matte￿ relaied to the impact of Brexit o
medicines regulations and me(Ji¢al research.

Drug Safety Research Trust
Trustees. Rep)rt
for tbe ye￿ Ended 31 De¢t￿ber 2025
OBJECTIVES AND AcfIvITIES
Significant activities
Rese#rch
The DSRU continues to function as one of the leadillg Ullits in the field of monitoring and $th￿yIng the Safety of
meth"cities both in the UK and iniernationally, as well as being a leading organisatiotL 111 teaching 22Jd training in these
fields.
Progress of the scientific work of the Unit was ￿tISfaCtory throughout 2025 and intluded ￿st authorisation ￿fety
studies (PASSI (many of which use Clinical Prdctice Research DataliTJk ICPRD) data). systematic reviews, dwg
utili5ation projects and methodological research. In addition, our programme of activities has included collab￿ating
with a b102d range of doctors in England through Health Research Networks from dEffering specialities 8$ well as
¢ollaboratiog with colleagues in Europe. The policy to extend the range of scientific activities. as funding allows, will
cottlinue.
Applications for fimding frorn bodies including grant-givillg bodie$. pharn￿￿tiCal companies and Europ¢an
initiatiY¢s, e.g., the European Commission, will eontinu¢.
The DSRU has a fornial collaborative partnership programme agreemen¢ wilh the NHS Business Services Authority to
receive prescripiton data that are neccssary to conduet Modified Prescription-Event Monitoring studies to improve the
understanding of the safety of new drugs ￿cd in the general population. This pajthership has the support of the
Dq)artm¢nt of H¢alth and senior staff at NHS Busin¢ss Services Authority.
Sin¢¢ application for Section 251 exernptiots of the NHS 2006 Act became a requirement, th¢ Trll5t has applied
annually to the Confidentiality Advisory Group (CAG} of the Health Research Authority for approval to use patient
data without ¢owent.
Edueatlo
The DSRU provides advic¢, education and training in pharmacovigilance and related subjects and works to improve
the methods used to study and understand the safety of medicit)es. As one of the mairt providers of training and
education in pham)a¢oYigilan¢e in Europe, its activities include..
Providing a rdnge of training courses in phamia¢ovigilanc¢ and phann•¢o¢piderniology. The DSRU Currently
provid¢s 12 courses per year, as well as a Postgraduate Certificate, Diploma and a Mastees degree in
Pham]a¢ovigilance in co112boration with University of Portsmouth and Phatma¢eutical Medicine Specialty Trainin8
(PMSTI for doctors specialising in plkarmaceutital medicine in collaboration with the Faculty of Pharniaceutical
Medicine.
- Providing external training and education when required.
- A￿Sing national and internationd confeTence5 ill phaMja￿vigllan¢¢ and phamiaco¢pidemiology.
- Providing postgtaduate teaching and research opporttmities at all l¢v¢ls.
- Providing training in pha￿￿rO¥lg]1ance and pharn)acoepid¢miology for phami￿¢Uti¢a1 physician5.
- Supporttng training and s¢icntsfi¢ communications on the safety of medicines in the UK and intemaiionally.
- Providing advice on ￿￿tte[S related to the safety of medicines.
- Producing newsletter5 and intetnet communications on matters to do with drug safety.

Drug S&f¢ty R￿earch Trust
Trustees, Report
for the Year Ended 31 December 21125
OBJECTIVES AND ACTIVITIES
Objectives
When rquired, report5 the results of studies are sent to the Medicines and H¢alih¢2re Products Regulatory
AuthOr￿ty IMHRA) lan executive agency of the Department of Health) and to the Europe2n Medicines Agency IEMAI
and other Regul￿Ory Authotities itt Europe to assist them in their regulatory and monitoring 2Ctivilies of medi¢ines.
The DSRU Sends reports of its Studies to Marketing Authorisation Holders of medicines and vaccines and also
publishes fjndings of its work in scientific journals and al national and Internation￿ conferences, newsletters and on
it9 website.
Attiwities
The rnain objeetlVC5 of the Unit for the next year are..
- Continuing with the Core activities of The utkit such as S￿dieS on the safety and utilisations of vaccines and medicinal
product5, benefit iisk assessments and risk minimisation activities.
- Itllplement a new busitiess strategy forthe coming years.
Trallsltion data analysis tools to keep up to date with the developments in the scientific world.
To Strett￿h¢ft the organisational stsucture so the DSRU can fuifjl it8 mission.
To have increased attention for the organisatiollal development so th¢ DSRU is a place wher¢ employees can d¢velop
professionally and wher¢ they feel at home.
Actively search for new business opportunities.
To continue to ty io secure suffJ¢ient fiinding from different sources (public and private) to enable the ¢ontinuation
of the charity's a¢tivities.
- Changing to a n¢w platforn for data capture.
Pvbllt benent
Th¢ Trustees ¢onfirni that the Charity Cotllmission's 8eneral guidance on public benefit h&s been considered in
relation to the Obl￿tiveS of th¢ charity.
The objectives, a¢tivities, perforniance and achievement sectton5 of this report clearly set out the activitie5 which the
charity undertakes for public benefit. Th¢ Trustees confirtn that they have complied with thcir duty in S￿tion 4 of the
Charities Act 2006 to have due regard to public benefits guidaTLce published by the Chariti¢5 CoTJUni5SiOll in
deterniining the activities undertaken by the chaTity.

Drug S4(tty Research Trust
Try5tees' Report
for the Year Ended 31 De¢ember 2025
ACHIEVEMENTS AND PERFORNIANCE
Charitable aetivitles
The su¢¢essful annual submission and Subsequent approval and support of the Ethics and Confidentiality Committee
of the Confidentiality Advisory Group ICAG) of the Health Research Authonty for Section 251 exemptioll vnder the
NHS Act 2006 was achieved for tb¢ sixteenth-y¢ar running.
The Certificate, Diploma and Masiers degree ID phanna￿vI81[ttn¢e ill collaboration the University of Portsmouth
Continued, with I15tud¢nts ¢nroll¢d at th¢ ¢nd of th¢ year.
Seven scientific papers wer¢ published in mcdic21 literature. Four abstr&ct&lposler presentations on tbe results of
studies were given by DSRU staff at national alld international medical and scientific Conferences. One Registry study,
one Drug btilisation S￿dY and five CPRD studies w¢re eonwleied attd delivered during 2025. In addition, one
interim report and two study progress reports were delivered. The DSRU has provided pharmacovigilance
consultanw support to phamweutical companies when requested.
Edu¢#tion and Prfrfesslonal Capablllty
The educational training of staff has been maintained in¢luding eontinuin8professii)tJal development.
Tfa¢hithg & Edueatio
The Head of Epidemiology alhd Reseateh tAught students at the University of Hertfordshire on their Msc
PharmacoYigiLance course. Ill addition, teaching and presenting at n&tional ond internat￿onal scielltific meetin8S
continued by both the DirectOT and 5¢nior scieTktifi¢ staff ¢ttablittg th¢ s¢ienttfic profile of the Unit aTLd its work in
public hea]th and drug safety to be maintained.
Tralnlng Courses for Pharmaceutical Medicine Sptei#llty Tralnlng
The DSRU continues to offer teaching courses in phaTmacoiigilan¢e, providing training on drug $￿ety module5 of
Pharn)aceutacal Medieine Specialty Training {PMST), for phanna¢¢uti¢al phy$ician$ on behalf of the Faculty of
Phamiaceutical Medicine, Royal College of Physicians.
Partners and StAkeholders
Uijiveisity of Portsmouth
The DSRU is an affiliate department of the University tsf Portsmouth and collaborations on jotnt stlldentships and joint
tr&inang continue.
Regulatory Agencies
Cli)se litths were maintained throughout the year with the Medicines and Healthcare product6 Regulatory Agency
IMHRA} and the European m￿lCineS Agency IEMAI wilh regular reports i>ll safety issues submitted, contributing to
the better understanding of the Safety of a number of important medicinal products. The DSRU 15 a member of the
Europvdn Network of Centr¢s for Pharnvdcoepidemiology and Pharma¢ovigilance IENCePPI, a project led by the
European Medicines Agency and developed in collaboration with European experts in the fields of
pharniacoepidemiolo8y and pharniacovigilance. Senior staff of the DSRU regularly participate in meetin8s of the
ENCePP network gFOUP.
VAC4EU
Th¢ DSRU is a member of VAC4EU which is a collaborative network of 28 member organisations acFOSS Europe
which ¢onduct studies on the safety 9nd effects"veness of vaccines. The network i5 Id by Ptofes50r MiTiaTn
StUTk¢nboom (the University of Utrecht in ihe Netherlattdsl. The DSRU is conductÈng one study on a COVID.19
vaccine and three sNdies on che RSV vaccine in Collabordtion with members of VAC4EU. The DSRU is using
Clinical Practice Research Daialink {CPRDI, the leading resource in the UK of primary care clinical data io conduct
these studies by Pfizer. white our collaborators are using databases in a nutthr of European countEtes.

Drug Sgfety Researth Trust
Tru5tee5' Report
for the Year EDded 31 DeCe￿ber 2025
International $cielltific leadership collaboration
The DSRU is leading aD Intetnational WO￿l￿g Group {IWG) for New Developments in PEwmacovigilance.
Group it]cludes solne of the best ¢xpert5 in the world iti ￿"$ field. The objective is tts identify aieas where
contributions can be n￿de lo advance methods used in pham¢ovigilan¢e and phamia¢oepidemiology. Such
developments include artificial intelligence llmchine learning, and the applicatitsn of geThetic knowledge in
detecting and evaluatsng adverse drug react10115. The wo& has progEessed well attd the results of the first wod(stregm
was pubhthed in 2025 with the result of the second workstteam due to be published in 2026.
Investment performance
The Trnstees are satisfied that the current investment approach of tbe Trust is consistent with its investment nee&,
objectiv¢s and attitude to risk, whsch is to provide F4 balanced return on investment ill the rnediutll term with a
i)derate risk of capital lo&s.
The retllm on investtnent incr&￿ed from £66.907 to £92,335 ill 2025.
FINANCIAL REVIEW
Flnanclal po$ltlon
The ac¢ounls have been prepared in accordance with the accounting policies set out in note I to the ¥¢ounts and
Comply with the ¢harity's Twst Deed, th¢ Charities A¢1 5993 and the Stst¢m¢nt of R¢comm¢nded Practice,
'A¢¢ouThting and ReportinÉ by Charities" issued in Mar¢h 2005.
The Statement of Finaneial Activities for the year is set out on page 15 to thc5e financial statements.
Prineipal funding $oure
Principal funding 50ur¢es come from dotjations r¢ceiv¢d from pharmaeeutical companies aDd other organisations in
OTdeT tt> caTry Out charitable 2Ctivilies.
Whilst some costs are provided ill advance by funders, the entitlement to income only arises when 5eparat¢ly
identifiable stsges of the projects are completed. The charity monitors the progress of the projects closely and only
intludes the income and associated costs as and when these conditions are md. Thi5 treatrn¢nt meets the charitys
accounting policy regarding incoming resource5 as set out under accounting policy 1.2 in the notes to the financial
$tatements.
StatTJng ¢osts {gross salaries plu5 employers, national insurance) in 2025 were £1.461.821 compared tt> £1.469.838 i
2024. Salarie$ still forni the major part of the charity's expenses due to ihe specialist nature of employees, e.g..
medical doctors &nd 5cientist5 lleeded to carry out the resear¢h activities. Ttsul wage ¢osis including naiion31
insuraE)ce and pensiort contributions therefore remain the highest expendittwe for the Tn￿1 on a year-by-year basis.
The Chaiman of Trustees and Director maintained ¢lose s¢n￿t￿Y of incoming resources and expendittwe during the
year and kept the Board infornied maintaining the same level of financial governaDce as in previous years.
Investment polley and objeetlves
Th¢ Trust has undertaken investment in equitEes and bond5 Ilwough Rathbortes {incory>otating Inve5te¢ Wealth &
Investment Ltd). In order to mOE)itor the investtn¢nt portfolio perfot]nance. two Trustees and the Director act as a
sub-conunittee. This group, on behalf of the Board of Tru5te¢s, deals with all matters relatiTh8 to the investment
portfolio and tneets Wlth r¢pT¢sentativ¢s of Rathbon¢s litt¢oJporating Investec Wealth & Investment Ltd) at
appropriate intetvals. It 15 the policy of the B()ard of Trustees that no ittvestments in the phomaceutical, armaments
or tobacco industrie5 should be undertaken.
Annually fro￿ a ￿anageMent perspe¢ts"ve all other fwids not immediately required from month to month for the
nortnal Tunning of ihe DSRU we routinely invested in fixed tern) deposit accounts to maximise return when¢Y¢r
P0$5ible.
The Ttust's slntegy to invest whenev¢r possible io offset for leaner years when donations are reduc¢L will b¢
mainlailled.

Drug Safety Research Trust
Trustees, Report
for the Year Ended 31 December 21125
FINANCIAL REVIEW
Re$erves poIiey
It is the w>liey of the charity to maintain wjrestricted fill￿s, w￿.Ch ale the free reserves of the Charity. This provides
sufficient funds to cover the eost of ongoing studies, managcment and administration Costs. Cottsidering expected
fluctwtions of futyre in¢ome, the f￿ancial res¢rves are ncccssary to maintain the future stability and viabiliry of the
DSRU. These reseryes will be used when and if fi￿d5 bccome too low to coycr no￿al day tt> day activities. In these
difficult economic timcs, the Trust is rcaping the benefit of the prudent finatscial policy in the last decade. This
approach will be ¢ontinucd in lin¢ with Ilcvclopm¢nts in thc ¢xt¢mal econorDie envÈroument.
A55et eover for funds
An analysi5 of the assets atttibutable to the various funds des¢ribed is set out in the notes to th¢s¢ financial statenLents.
Tbese assets are sutTicient to meet the charity's obligations on a fund-by-thnd basis.
Going ¢oncerD
The Trustees CODsider the fjnancial. operatill8 alld other tisk factots when assessing whether there is any signifi¢ant
doubt over the Trust's ¥4bility to eontlnue as a going concem.
Dllring its 40 plu5 years. the Trust ha5 e5¢ablished and followed a policy designed to ensure that, in th¢ highly unlikely
event of a significant dTOP In income. it ha5 sufficient cash and CAsh equivalent reserves to enable it to wntinue its
¢harit2ble activities for & period of at least 2 y¢ars. The TnEStees have considered the level of funds held and the
expected level of income and eKPtnditure for 12 months from authorisitss th¢s¢ fin3n¢tal $tatem¢nts. The budgeted
incotne and expenditure is sulTicient with the level of reserves for the charity to be able to continue &s a going concern.
Since BrexiL theTe has bttn some uncertainty over the currettt regulatory environment and the impact this may have
on the Trust's fullding. The Ttust is actively moniioritig and planning for any ¢han8e$, including repositioning itself
to illciease th¢ numbei of studies b¢ingperfonn¢d in th¢ UK.
Because of the healthy level of "free reserves" and th¢ operational steps taken to ty 2nd ensure that the Tr￿t remaitts
at the forefront of monitorillg and research in ihe field of pharmacovigilance and phanllacoepidetniology. the TTU5tees
do not believe ihere is any such doubt and th¢r¢foTe b¢li¢ve it is appropriate to use the going concetn basis of
prepardtion in the8¢ fillan¢ial s(at¢m¢nis.
FUTURE PLANS
Due to the new regulatory environment after Brexit the overall business strategy of the Unit has been reviewed and a
new business Strategy has been developed and is being implem¢nt¢d.
The Unit will Continue io conduct a broad range of studi¢$ to address safety questions, including observatio1￿ studies
using bespoke data colledion. pharniacoepi(lemiological studies using already existing data sourcE5 and a Tange of
different stL￿Y designs, such as drug and vaccine utilisation studies, meta-analyses, SYSten￿tiC review5, benefit-risk
evaluations. Other 8tt￿Y meihods to understand drugs and va¢¢ines safety, effectiveness use and utilR5ation.
The DSRU will ltrdd or participate in national and international collaborative projects that aiTn to improve the methods
and advan¢e the science of studying the safety of medicines. The DSRU wryll further develop its scientifi¢
tommunications programme to infomi the both the medicavseientific conllnunitics aTLd the publi¢ alx)ut important
phaMa¢ovi￿1att¢e issues.
The Unit will further develap its methods and capabilities in evidence-ba5ed phaTmacovigilan¢e and risk management
and maintain its place as a leading Unit providing advice, trailling and education in phamiacovigilance and drug
safery.

Drug Safety Rese3rch Trust
Trustees, Report
for the Year Ended 31 Decembtr 2025
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The Trust is governed by a chatitable Ttusi Deed esiaiTrlished on 23 July 1986 with a Board of TTU5t¢es five in numb¢r.
The Mission of the TTU5t iemain5 to ￿ts￿lI0r. S￿dY and communicate the safety of medicines indep¢nd¢nt from both
Govenunent and industry. The TtU5t by way of its operational unit, the Drug Safety Research Unit IDSRU),
ndertakes all forms of 5tudie5 and evaluations on the safety of medicines. The DSRU provides advice, training and
education in phannacovigilance and reLated subjects and works io improve the methods used to S￿dY and understand
the safety of medicines.
As an illdependent registered medical chariry, its aim is to achieve the highest possible s¢ientific and ¢thicai standard$
by putting the interests of patients first and lo work with integrity and faim¢ss with all partners.
Reeruitillent and appointment of lleiv trustees
As a charity specialising drug safety. the Tn￿teeS are identified for their expettise in areas which in¢lud¢ thg
regulation, epidemiology and medical statistics, experimental medicine and pl￿rn￿¢￿VigIlan¢e. Once 8ptx>inted, th¢
Trust ensure5 that any trdining r4uired by the Tn￿re¢S is provided to enable them to fulfil their rol¢.
Trustees of the charity
The Tn￿le£S acknowledge their re5ponsibililies as set out on the statement of Tjusiees responsibiliiies.
Th¢ Trustees wkn have servcd thiring the year and sinee the year end were as follows..
Professor Kenneth Ross Paterson MB ChB FRCP FFPM FBPhS (chaim￿ll)
Professor John Camm MD. Fmedsci, FRCP(L,E&G), FESC, FACC, FAHA, FEHRA, FHRS, FBCS, FBHRS,
FAL4,CStJ
Professor Martin Vessey CBE MD FRCP FRCOG FRCGP FFPH FM¢dS¢i FRS
Professor Allan Hunter Young MB, ChB, MPhil, PhD, FRCPC, FRCPsychP
Proftssor Isla M&ckenzie MB ChB PhD PGCertMedEd FRCP Edin FBPhS FBIHS
There have been no changes to the Trustees in the year nor to the date of sigtiing of the5¢ financial statements.
Or¥y4nia*iion#l strne￿re
The TtU5t employs a DIr￿tOr, assisted by Scientific, professional and administrative staff to conduct its day-to4iay
activities. ensuring that the Charity's objectives are implemented. The Trust also r¢tains the services of appropriate
advisers and consultants depending upon the nature of the tssks required. During 2025 the average number of staff
employed for the year was 26. In addition, 11 consultants were engaged, to advise and assist with additiOTLal
medi¢aVresear¢h inpu¢ IT and data protection, PRlmarketin8, planning matters, business strategy and prof¢s5ional
development.
Induetion and tralnlng of new trustees
Induction is tailored to meet the needs of any new Tn]stee and will be detemiitted based on their own knowledge and
exptrience. Whete neLessary, tsxining is provided on charity, governance and financial matters.
Key managemettt rernulleratloll
Th¢ Trustees, in conjunction with the Director where appropriate, are responsibl¢ for setting the pay and remuneration
of k¢y tnanagement.

Drng Safety Research Trust
Truste¢s' Report
for the Year Ended 31 December 2025
STRUCTURE, GOVERNANCE AND TrL4NAGEMENr
Risk management
The Tntstees have a thEty to idet)tify alld review the risks to wbich the charity is exposed and to ensur¢ appropriate
Controls are in place t(p provide reasonable assllrance against fraud and error.
The Trusiees exaniine the major strategic, busines5 a[￿ operational risks and confinn that systems ar¢ established to
enable regular retx)rts to be produced, so that necessary steps can be taken to control or lessen these risks. The
variabiliiy of the funding of the Trust made it necessary to put in place processes io ensure that staff felt secure and
motivated.
A Disaster Re¢overy Pian for the DSRU ha5 been designed aThd eompleteiL The plan is secwed in off-site storage
ithin a data safe.
Approved by older of the board of trllstees on.............
. and signed on its behalf by..
Professor K R Pat¢rson MB ChB FRCP FFPM- Trustee

Drug Safety Research Trllst
State￿ettt of Tru5tees' Responslbi]ities
for th¢ Y¢ar Ended 31 Decejnber 2025
The truste¢s are r¢sponsibl¢ for pr¢paring the Trustees, Report and th¢ finawial stal¢m¢nls in accordance with
applicable law and United Kingdom Awountlllg St&tthrds (United Kingdom G¢n¢rally Acc¢pt¢d ACCo￿nting
Practice) including Financial Reportittg Standard 102 "The FinarLcial Rq)orting Standard applicable in the UK at
Republic of Ireland".
C1￿]ty law r¢wires tbe trustees to prepare fillancial ststements for each f]nancial year. Under that law, th¢ tNst¢¢s
have elect¢d to prepare the f￿ancIal statements in accordance with United Kingdom G¢nerdlly A¢¢¢pted A¢¢ounting
Practice {United Kingdom AccountiiL8 Standard5 and applicable law).
Under charity law the trustee5 must not approve the fil￿ncIal statement5 unles5 they are satisfied that they give 2 true
alld fair view of the state of affairs of the charity and of the Enco￿l￿g re50urce5 and application of resources. illcluding
the incoille and expenditure, of the chatity for that period. In ptq)aTitEg those financial statemellt5, the trustees are
requited to
select suitable accounting policies and th¢n apply Iheth collsistently.
obsenre the tnethods and principles in the Chariiies SORP,.
make judgetnents and estimates that are reasonable and pn￿¢￿t.
state whether applicable a¢¢ounting standards have been followed, subject to any material departtu¢s disclosed and
explained in the financial statemenis,.
prepare the financial statements on the going ¢on¢ern basis ull1¢58 It is inappropriate to presume that the charity
will continue in business.
The tn]stees ale responsible for keeping proper aceounling records which disclose with reasonabl¢ a¢¢urd¢y at any
time the fEnancial position of the chatity and to enable them to ellsiire that the financial statements c<)mply with th¢
Charities Act 2011 and The Charity (Accounts and Reports) Regulations 2008. They are also responsible for
safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud
and other irregularities.
-1

Report of the Independent Auditors to the Trustee5 of
Drug Safety ReseY4rch Trust
Oplnion
We have audited the fU￿n¢la1 statements of Drn8 Safety Research Tn￿t (th¢ '¢harityl) for the year ellded
31 December 2025 which ¢ompris¢ the Staternellt of Financial Activities, the Slaiemenl of Financial PosÉtion, the
Statement of Cash Flows and llotes to the f]n2ncial statcments. itkcluding a sunllll2ry of significant accounting
policies. Th¢ fuwicial r¢porting framework that has been applied in their preparation is applicable law al￿ United
Kmgdom Accounting Standards {Ullited Kin8dorn Generally A¢¢epled Accounting Prdcticel, including Fillancial
Reporting Standard 102'Th¢ Finawial ReportiEJ8 Standard applicable in the UK and Republic of ITelaNI'.
Ill our opinion the financial statem¢nts.'
give a t￿￿ and fair vt¢w of th¢ State of the charity'5 affairs as ai 31 December 2025 and of its inciTrmiDg resourtes
and application of resources, forthe year then ended,.
have been properly prepared in accordance with United Kingdom Generally AccepÉ¢d A￿u￿ting PractÈ¢e.
in¢luding Financial Rep)rting Stalldard 102 'Th¢ Financial ReportitEg Standard applicabl¢ in the UK atHI Republic
of Ireland and
have been prepared in accordance with the requirements of the Charities Act 2011.
Bas1$ for oplnion
We condu¢*d our audit in accordance with Illtemational Standard5 on Auditing (UK) {ISAs (UK)) and appli¢abl¢
law. Our responsibilities under those st*tMlar(ts are further described in the Auditors, iesponsibilities for the audit of
the financial statements sedion of ollr ￿POrt. We are independent of the charity in &ccordattc¢ with the ¢thicAI
requirements that are relevant to ow audit of the financial 5tatemetsts in the UK including th¢ FRC'S Ethical
Standard, and we have fuifjlled our other ethical responsibilities in accordance th¢se requirements. We b¢lieve
that the auth"t evidence we have obtained is $utTicient and appropriate to provtde a basis for our opinion,
Conelusffions rei#t5ng to going Concern
In audiling the financial statemen￿ we have concluded that the trustees, use of ttle going Concern basis of a¢¢ounting
in the preparation of the financial statements is appropriate.
Based on the WO￿ we have perfOrn￿(l we have not identified any ￿￿terIal un¢ert&inti¢s ￿lati1]s to events or
conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a goin8
concern for a period of ai least twelve months from whell the financial staÉtments are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going con¢em are d¢s¢ribed in the relevant
s¢¢ti0115 of this report.
Other infortThation
The trustee5 arc F¢5ponsible for the oth¢r inf0m￿tiOn. The Oth￿ inf0m￿tion COFnprises the inf0m￿tIOn in¢lud¢d in
the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.
Our opinion on the finan¢ial statements does not cover the other Enfommtion and. except to the extent othen¥ise
explicitly stated in our repo¢ we do not express any forni of &ssurance conclusion thereon.
tn connection with our audit of the financial statem¢nts, our responsibility is to ￿ad the other infonnation and, in
doing 50, ronsi&r whtthtr the other informatiorj is materially inconsistent with the fJnanci&l statelnents or our
knowledge obtained in th¢ audit or othenvi5e appears to be maierially misstaied. If we identify such material
incoiLSl5ten¢ies or appartnt material mi5Statements, we are required to d¢temiin¢ whether this gives rise to a material
In15Stat¢Trent in the fittancial statemcnts themselves. If, based on the work we have perforn)td, we conclude that there
15 a rtlaterial misstaiemeni of this other infortnatioN we are required to repott that fact. We have nothillg to report in
this regar
Matter5 on whi¢h we Are required to report by ¢x¢eptioD
We have nothing to report in respect of the following matters where the Cltsrities {Accounts and Reports) Reglllations
2008 requires us to tH)Ort to you if, in our opinion..
tILe information given in ihe Iruslees R¢port is incon5iStent in aDy material respeci with the fjnancial slatements: or
sufficient *c¢ountittg records have not be¢n kept. or
tILe finallciaj statements are not in agreement with th¢ accouutiIi8 records and reNtrns: or
we have not received the information and ¢xplaDatioll$ we requÈre for our audil.

Report of the IndepeMd¢nt Auditors to the Tru$tee$ of
Drug Safety Research Trust
Responsibilities of trustees
As explained more fully in the Statement of TrusÉee5' Responsibilities, the trL]slees are responsible for the preparation
of the financial ststements which give a tnte and fair view, and for such internal control as the tjustees detem)ine is
necessary to enable the preparation of flnancial statements that arc frcc from material mtsstatemenl, whether due to
fraud or ¢rror.
In preparing the fLDaneial statements, the trustees are respoajsible for assessing the charity's ability to continue as &
going concern, disclosing, as applicable, matters rclatcd to going concern and using the going Concern basis of
accounting unless the trLtstees either intend to liquidate the charity or to cease opcrations, or havt no rcali$tic
alternative but to do so.
-12-

Report of tbe Independent Auditors to th¢ Trustees of
Drug Safety Research Trust
Our responsibilities for the audit of the fmancial Statements
We have been apBx)inted as auditors under Section 144 of the Cknitics Act 2011 and report in a¢cordance with th¢
Art and relevant regulations made or having effect thereunder.
Our objectives are to obtain reasoDable assurance about whether the fUM￿la1 sratements as a whol¢ are free from
material misstatemen¢ whether due to fraud or error, alld to l5sue a Report of the Independent Auditors that ￿ClUdeS
our opinion. Rezsonabl¢ as8urance is a high level of &ssurance. but is TEOt a guarantee That an audit conducted in
accordance with ISAS IUKI will always detect a material misstatemellÉ when it exists. Misstatements can arise from
frdud or error and arc consid¢red material if, individually or in the Aggregaie, they could reasonably be ¢xpect¢d to
influen¢e the economic dccisions of u5crs tak¢n on the b&si$ of these financial statements.
The extent to which ourpro¢¢dvres ar¢ ￿pable of d¢t¢ctillg irregularities, fftncluding fydud is detail￿ below..
We ensured that the ¢nga8ement tealn eollectively had the appropriate competence. capabilities 2nd skills to identify
or recognise non-¢ompliance with applicable laws and regulations. and that th¢y remained alert to illstallces of
non-complion¢e throughout th¢ avdit.
r approach to identifyllig and assessing the risks of material missiatement in respect of irre￿ities, including
fraud and non-¢ompliance with laws and regulations. was as follows..
- ba%d on our understanding of the ch￿lty and sector. and through discussions with twstees and key management, we
identified ally sp¢¢ifi¢ laws and regulation5 which we conside￿d may have a direct material effect on the financial
stalemet)ts or the operation5 of the charity, includiDg th¢ SORP 2015, Comp2nies Aci 2006, t*LKation legislation Rnd
data protection, &nti-bribery. eTnploymenL environmental attd health and safery Itgislation,. and
we a&ses5ed the extellt of con]pliance with these laws and regulations through making enquiri&% of management and
inspecting le8al correspondence.
We assessed the sU￿¢ptibl]Ity of the charÉty'$ finantjAI statemettts to m&terial mi&thtem¢nL including obtaining an
understanding of how ftaud might o¢¢ur, by..
- n￿king enquirie5 of Tnanagemtnt as to where they considered th¢r¢ w&8 susceptibility to fraud. their knowledge of
actual, 5USP¢Cted and alleged fraud. and
- eonsideTill8 tht internal controls in place to mitigate risks of fraud and non-¢(Fmpliance with laws and regulations.
To addtess the risk of fraud through management bias and ovetTide of contro15, we..
- P¢TfcTmed analytical procedures to identify any unusual or unexpected relationships.
- tested journal entri¢s, particularly focused around the Yt￿r-end, to identify unusual tran5aciiotts',
a55e5sed whether judgements and assumptlODS made in deterniiniTrg the accounting estimates in the notes to the
finan¢i&l statements were indi¢aiiv¢ of potential bias.. and
- invesiigated the Tational¢ behind significant or unusual transactions.
In response to the risk of irregulari¢i¢s and non-complianee with laws and regulation& we designed pr(￿dureS which
included, but were not limited to..
- agreeing finat)cial statement disc105ures to underlying supporting documet)ÉatioJ;
- reading the minutes of meetings of those Charg￿ with gove￿anlY.,
- enquiring of managetnent as to actual and potential litigation and clitims: and
- reviewing ¢orrespondenoe with HMRC, relevant regulators and the chaTiry'S legai advisors.
There are illhe￿nt limitations in the audit proctdutes d¢5CTibed above. We are less likely to become aware of instances
of ni>n-¢omplianct with law5 atld regulations that ate not closely Telaled to events and transactions reflected in the
finan¢ial stat¢ments. Also. the risk of not detecting a mat¢iial misstatemettt due to fraud is higher than the risk of tjot
deteciing on¢ resuitillg frorn error, as fraud may invtslve dehbetate ¢on¢ealment by, for example, forgery or intentional
misrepresentatLons. or through cotiusion.
A further description of OUT r¢5pon5ibilitie5 foi the audit of the financial statements is located on the Financial
Reporting Coullcil'5 website at www.frc.org.uklauditorsresponsibilities. This description forms part of our Report of
th¢ Independent Auditor5.
-13-

Report of the Independent Auditor5 to the Trustees of
Drug Safety Research Tr￿st
Us¢ of report
This r¢port is made sol¢ly to the charity's ttustees. &$ a body, in accordallce with Part 4 of th¢ Charities (Accounts and
Reports) Regulations 2008. Our audit work has been undertak¢ll so that we might stale to the ¢lwitys trnstees those
matters we are required to stat¢ to them in an auditor5. rtport alld for no other pU￿Ose. To tbe fi]Ilest extent perniitted
by law, we do not accq)t or assume responsibility io a￿yOne other than the charity and the charity'5 tn￿te¢S as a body,
for our audit work, for tbis repo¢ or for the opillions we have f0rll￿i.
cart￿ryi8￿ts
Chartered Aecoulltants and Bu5illess Advi50ts
sta￿tory Auditor
Regency House
33 Wood Street
Bamet
Hertfordshire
EN5 4BE
Date..
zaz6
Andrew Hill FCA {Senior sts￿tOry Auditor) for and on behalf of Cartwrights
-14-

Drug Safety Research Trust
Staternent •f Fitianel41 Aetlvltles
for the YeAr Ended 31 December 202S
31112125
Tot41
funds
31112124
Total
fuDds
Unrestricted
fund$
Restrlcted
ruDd
Notes
INCO14￿ ALW ENDOITrTrqENTS FROM
Donations 41ttd l¢gaLies
958,187
958.187
704,584
Inves¢ment income
Oth¢r income
257,075
35,665
257.075
35.665
234.799
233,762
Tot81
1250,927
1,250,927
1,173,145
EXPENDITURE ON
Raising funds
24,341
24,341
24,633
CkArltable acthdtles
Direct Charitabl¢ Expenditure
1,433,979
18,780
1,452.759
1,706,844
Oth¢r
765,871
765,871
746,924
Total
2,224,191
18,780
2,242,971
2,478.401
Net gains on investments
209,474
209,474
113,703
NET INCOMEIIEXPENDrruRE)
(763.790)
(18,780)
(782,570) (1,191,553)
RECONCILIATION OF FUNDS
Total ￿ndS brought forward
6.866,214
415,500
7,281,714
8,473,267
TOTAL FUNDS CAIiBJED FORWARD
6,102,424
396.720
6.499.144
7,281,714
The note5 form part of these financial statements
-15-

Drug Safety Research Trust
St4tem¢nt of FinAnciAI Positiom
31 December 2025
31112125
Total
funds
31112124
Total
funds
Unrestrlcted
fund5
RestrieÉed
fund
Notes
FIXED ASSETS
TatTrgible assets
Ye5¢n￿lts
67.832
4,220,406
396,720
464,552
4,220,406
459,704
4,311.066
12
4.288.238
396.720
4,684,958
4.770,770
CURRENT ASSETS
Debtors
Cash at b&nk
13
323,617
1.564.875
323,617
1,564,875
500,4(X)
2,091,721
1.888,492
1.888,492
2,592,121
CREDITORS
Amounts falling due withÈn one year
14
(74.306)
{74,306)
(81,177)
NET CURRENT ASSETS
1.814.186
1.814,186
2,510,944
TOTAL ASSETS LESS CURRENT
LIABILITIES
6,102,424
396.720
6,499,144
7,281,714
NET ASSETS
6,102,424
396,720
6,499,144
7,281,714
FUNDS
Unrestricted funds
R¢stri¢t¢d fithds
15
6.102,424
396,720
6,866,214
415,500
TOTAL FUNDS
6.499,144
7,281,714
The financial staiements were approved by the Board of Tn￿te¢S and authorised for issue
. and were signed on its behalf by..
on
K R Paterson MB ChB FRCP FFPM- TrL]Stee
Th¢ llot¢s f<)nn part of th¢se finan¢ial ststements
-16-

Drug Safety Research Trust
Statemellt of Cash Flows
for tbe Year End¢d 31 Dece￿￿er 2025
31112125
31112124
Notes
Cash flows from operating a¢tivitie5
Cash generated from operations
1925.043)
(902,4201
Net cash used in operatillg activitie5
1925.043)
1902,420}
Cash flows fro￿ investing #ctivitie$
Purchase of tangible fix￿ assets
Purchase of fixed asset investtnents
Sale of tangible fLxed assets
Sale of fixed asset illvestments
Interest received
Dividends received
(45,927)
1199.866)
(12,451)
1130,535)
1,109
113,703
126,(A3
66,907
500.000
51.656
92.335
Net cash provided by investing activities
398.197
IrfA,776
Change in cash and cash equivalettt$ irt
the rcportlng period
Cash and e2sb equlvalents at th¢
beglnnlng of the reporting perIod
{526,846)
1737.644)
11)91,721
2,829,365
C#sh and eash equlv8lents At the eDd of
the reporti￿% period
1,564.875
2,091,721
The noies forni part of these fin&ncial 5taternents
-17-

D￿g Safety Research Trust
Notes to the Statement of Cash Flows
for the Year Ended 31 December 2025
RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING
ACTIVITIES
31112125
31112124
Net expendlture for the reportlDg period la$ per the Stst¢m¢nt of
FiDaThcial Activities)
Adjustments for:
D¢preciation ¢harges
Oain on investments
Loss on disposal of fixed assets
Ittt¢r¢st received
Dividends received
Decrease in debtors
Decrease in creditors
(782.570) (1.191,553)
38,508
1209,4741
2,572
151,6561
(92,335)
176.783
{6.8711
31,669
{227.4061
{126,0431
(66,907)
711.557
(33.7371
Nel cash used in operations
{925,043)
{902,420)
ANALYSIS OF CHANGES IN NET FUNDS
At 111125
Ca$h fiow
At 31112125
Net cash
Cash at bank
2,091,721
1526,846)
1,564,875
2,091.721
1526,846>
,564,875
Total
2,091,721
1526,846}
1,564,875
The notes fomi part of these financial statements
-18-

Drug Safety Research Trust
Notes to the Fknancixl Stitements
for the Year Ended 31 December 2025
ACCOUNTING POLICIES
Basis of prep4riDg tbe fillanelal statemeDts
The f]nancial statements of the chariry. whicb is a public benefit entity urAder FRS 102, have been prepated i
accoidanee with the Chatities SORP (FRS 102) 'Accounting and Reporting by Charities-. Statement of
Recommended Ptaetiee applicable io clmrities prepartng their accounts in a¢cordallce with the Financial
Reporting Standard applicable in the UK and Repubhc of Ireland IFRS 102) (¢ffective l Jalluary 2019),,
Financial Reporting Standard 102 'The Financial Reporting Standard applicable ill the UK and Republic 0£
Irelalld, and the Charities Act 2011. The f￿ancial sta*ments have be¢ll prepared under the histotical c05t
convention. with the exttption of investments which are included at market value, as ￿odified by the
revaluation of certain assets.
Going concern
These ftnancial statemenis are prepared on the going concern basis. The trustees have a reasonable expectation
that the charity will continue in operational existence for the foreseeable ￿t￿re. The validity of thi5 8SSUtnption
depends on the continuing surylus in free resetves. If the ¢hartry were lltiable to continue in exL5tence for the
foreseeable thture. adjusiments would be necessary to reduce the balance sheet values of assets to their
recoverable amounts and to reclassify fixed assets as current assets.
Critit#l *eeoumtillg judgements and key sources of estImatl&￿ un¢ertalnty
Judgement5 and estimates are continually evaluated and are based on historical experience and other factors.
including expectatiolls of fvture events that are believed to be reasonable under the circutnStatLce5.
ritical accountin
estitnates and assum
lions
The charity makes estimates and assumpliotts concerning the fijture. The resultin8 accounting ¢stimat¢s wilL
by definitton, seldom equal ihe related actual reslllÉs.
Propety, plant and equipment
tat)gible fixed assets are deprcciated over their useful lives taking into
accounts residual value, where appropriate. The actual IEves of the assets atMI residual values are assessed
onrtually and may vary depetsdittg ott a sjwnber of factors. Residual value a5se5sments Gonsider issu¢s su¢h as
th¢ remaining life of the asset and projected disposal values.
Re¢ognItio￿ of income - income is recognised when receipt is probable and when the amount Can be measured
liably. At the end of the financial y&qr all ongoing studies are reviewed and a¢¢rL￿d income ests"mated from
th¢ available inf0m￿tIOn, based on the fvlfilment of the sttmly coDditiOll5 andlor mil¢sion¢s.
Income
All incoThe is T¢¢ognised in the Statemeni of Financial ActÉYities onc¢ the charity has entitlement to the fi￿ds.
it is probabl¢ that the incotne will be received and the amount can be measured reliably.
Foi donations to be re¢ognised the charity will have be¢n notified of the amounis and the sdtlement date in
wtiling. If there are conditions attached to the donation and this requires a level of perf0m￿ll¢e before
¢TLtitlement Can be obtained thet) incomc is dcfcrrcd until those condilioll$ are fully met or The fvlfilment of
Ih05e conditions is within the control of the Charity at)d it 1$ probable that they will be fulfilled.
Jnvestment income is eamed through holding assets for investment putposes such as shares. It includes
dividends, interesi and unr¢alis¢d gains or losses on shares held Where it is ttot practicable lo identify
investmeni management ¢osrs in¢urred within a scheme with reastsnt4ble accuracy ihe investment income is
reported net of these costs. It is included when the amount can be measured reliably. Inierest income is
recosnis¢d using th¢ eff¢dive int¢re$t method and dividend incotne is recognised as the charity's right to
receive payment is estoblishe
-19-
continued..

Drug Safety Research Trust
Not¢$ to the FinAn¢ial Statements- ¢ontinu¢d
for the Year Ended 31 Deeember 2025
ACCOUIYTING POLICIES- continued
Other income represents man2gement fees charged 2nd donations received from the Trust's Col￿t¢led trading
entity, DSRU Education and Resear¢h Limited. Management fees are included when charged atsd donatLOIiS
when received. Due to the cotllJe¢led tsa￿re of this entity, donation income is re¢orded within other income
rather than within dol￿tiOnS and legacy income in the Siatemettt of Financial Activities.
DebtQTS ar¢ recognised when the charity is legaily entitled to the income after ooy perfornan¢e conditions have
been mel, the amount can be measured reliably and it is probable that the income will be received.
Expettditure
Liabilities are re¢ogThised as expendi￿re as sTh)n as there is a legal or cothsttNciive obligation committing the
charity Its that expendiwle, it is probable that a transfer of economi¢ benefits wll be required in settlement and
the amouni of ihe obligation can be measured reliably, Expendiwre is accounted for on an aCfflTals basis and
has been classified under headings that aggregate all cost related to the Category. Where costs cannot be
directly attributed to particular headings they have been allocat¢d to activities on a basis consistent with the use
of resources.
Ralsing funds
Cost5 of raising fLmds represent investment manager costs incurred in dealing with the listed investment
portfolio
Charitable attivities
Expenditure on ch￿ltable actiwities includes the dii¢¢t cost5 OtcaTrying out and performing the studics and
evaluations of ]nedicines in order to meet the chatity's objectives and all￿.
Allocation aDd apportionment of eosts
Support costs are those that a5Sl5t the work of the charity but do not directly represent charitable activities and
include oflice costs. governance costs. adTnini5trative payroll cost5. They are incurred directly in support of
expenditure on the object5 of the charity. Where support costs cannot be directly attributed to particular
headings they have been allocated to cost of T&15ing ￿[1d5 aTJd expenditure on charitable actiTritie5 on a basis
consistent with use of the resources.
Tangible fixed a55ets
Tangible fixed assets other than freehold land are Stated at cost less depreci2tion. Depreciation i5 provided at
rates calculated to write off the cost less estimated ressdual value of each asset over its expected ￿eful life. as
follow..
Freehold land
Not depreciated
Freehold buildings
2/D Straight line on cosi
Plant and m&¢hinery
20/0 straight line ot) ¢tsst
Fixtures. fittsngs and equipment 20/0 Straighi line on cosi
Motor vehicles
20/0 Styaight line on co
Taxation
The charity is an exempt charity Within the meaning of s¢hedul¢ 3 of the Chtritie5 Act 2011 and is consi(kred
to pass the tests to ensure it is exempi from tax on its ¢hariiable activities.
Fund a¢couttting
Unr¢sirict¢d funds ¢an ￿ us¢d in acconknce with th¢ ¢haTitabl¢ obje¢tiY¢s at th¢ diwr¢tion of the irust¢es.
Restricted futMLs call only be used for partitular restricted purw5es within the objects of the charity.
Restrictions arise when specified by the dtsnor or when funds are raised for particular restricted purposes.
Further explanation of the nature alld pury)ose of each fL￿d is illcluded in the notes to the finaDcial 5tatemellt$.
-20-
continued...

Drug Safety Researeh Trust
Notes to the FirAan¢ial StatemeDts- contilllled
for the Year Ellded 31 Decemb¢T 2025
ACCOUNTING POLICIES- contAnued
Forelgn eurrencles
Assets and liabilities ill foreign currencies are Iranslaied into st¢rliDg at the rates of exchange ruling at the
statement of f￿anCIal position date. Transactions in foreign currencies are translated into sterlin8 at the rat¢
of exchange wling at the date of tsallsaction. Exchange differences are takell into acwut)t in arrivin8 at the
operating resulL
Pellsloll Costs And other post-retirement benefits
The charity operatts a defined contriblltion pension sche]ne. Contributions payable to the ¢harit)es peDSiOll
8ehetlle are charged to the ststement of Financial Activitie5 ill the period to which they relat¢.
Don8ted goods
The ¢harity does llot receive ally donated goods or gifts in kind.
Flnanel41 Instrument5
The charity only holds basic f￿ancial it]strumellts a5 def]ned in FRS 102. The fJnaDcial assets and finaneial
liabiliiies of the charity aThl their me&sureTnent basis we as follows..
Financial ass
Fiyed asset investments publicly traded fi]nds and shares are basic financial instrnm¢nts and are measured at
fair value with Changes in fair value recognÈsed in the StateTneD¢ of Finan¢ial Activities.
Trad¢ other debtors are basic financial instruments and ar¢ d¢bt instruments measured at amortised cost as
detailed in the debtors note to the5¢ financial statements. Fr¢payn￿nts and accrued income are not fit)ancial
instrnrnents.
C&8h at ballk- is cla55ified as a basic financial instrnment and is measured at face value.
Financial liabilitie5
Trade creditors and otheT cieditors are basi¢ financial instn]ments, and are measured at amortised cost &8
detailed in the creditors note to these fingn¢ial statements. T￿tion and social se¢urity are noi included in thc
finallcial instTuinents disclosure d¢fJnition. Accruals and deferred iThcornt is noi deemed to be a financial
liability, a5 the cash settlement has already taken place and there is an obligatiim to deliver services rather than
cash or another finaijcial instnmient.
Other bAlante sbeet items
Cash at bank and hand inclEuled cash and short terni highly liquid inve5tment5 with a short mati]rity of
three months or less from th6 date of acquisiiion or opening of the deposit or 5iTnilar account.
Provisions are recognised wh¢n the Charity has at) obllgation at the tH>Orting dat¢ as a result of a past event
whieh it 15 probthle will result in the transfer of economic benefits and the obligation Can be estimated reliably.
ProvisioDS aTe measured at the best estimate of the amounts required to Settle the obligation. Where the effect
of the time value of money is maierial, the provision is b&%ed on tht present value of those amowits, dis¢ount¢d
at the pre-tax di5COLirit rate that reflects the risks $￿CIfiC to the liability. The unwinding of the di%ount is
recognised within interest payabl¢ at)d simil2r charye5.
-21-
¢onlinued...

Drug Safety Res¢9r¢h TTll$t
Notes to the Fin*n¢i41 Statements- eontinued
for the Year Ellded 31 December 2025
DONATIOf4S AND LEGACIES
31112125
Total
funds
31112124
Total
funds
Unr¢5tri¢ted
funds
Restrl¢ted
f￿ndS
Dollatiolls
958,187
958,187
704,584
Ir4VESTMENT INCOME
31112n5
Total
funds
31112124
Totsl
funds
Uttre$trict¢d R¢stri¢ted
funds
funds
Gain on dtsposal of investment
Listed in¢ollLe
Interest ie¢eived
113,084
92,335
51,656
l 13.084
92,335
51,656
41,849
66,907
126,043
257,075
257,075
234,799
OTHER INCOME
31112125
Total
funds
31112124
Total
fund$
Unrestrlcted
funds
Restricted
funds
Other incom¢
35,665
35,665
233,762
RAISIIYG FUNDS
lrtvestment management costs
31112125
Totsl
funds
31112124
Total
funds
Unrestrltted
funds
Restricted
funds
Fund mallag¢r costs
24,341
24,341
24,633
CHARITABLE ACTIVITIES COSTS
Support
costs {5ee
not¢ 7)
Dlrect
Costs
Totals
Direct Charitable Expenditure
1,450.187
2,572
1.452,759
continued...

Drug Safety ReseAr¢h Trust
Note5 to the FiDaDcial StAtements- contlnmed
for the Year Ended 31 DeCe￿ber 2025
SUPPORT COSTS
Governance
Fln#n¢e
Totals
Other ie50urces expended
Direct Clwitable Expenditure
765.871
765.871
2,572
2.572
2,572
765.871
768.443
Support C05t4 included in ihe aboye, are as follows.-
31112125
31112124
Otber
resources
expended
Direet
Charitable
Expelldl￿re
Total
actlvitles
Total
ctlvities
Loss on sale of tangible fixed assets
Wages
Social security
Pen5iOnS
Auditors, remuneralio
Auditors, remuneration for non audit work
Rates and water
Insurance
Light and heat
Telephone and fax
pps
Sundries
Repairs and n)aintellan¢e
Staflmedical costs
Motor and ttavel expenses
Computer costs
Subscripiiorts
Bank charges
Marketing costs
Equipjnent hire
Depreciation of tangible fixed assets
2,572
2,572
181,354
159,023
105,712
16,090
2220
12,537
24J66
29.605
2.045
1.496
11,152
29,859
5,642
49,140
16,954
47,418
824
30,074
1,852
38,508
181.354
159,023
105,712
I6,(￿0
2,220
12,537
24,366
29,605
2,(WS
1,496
11.152
29.859
5.642
49,140
16,954
47.418
824
30,074
1,852
38,508
178,021
150,351
97.095
11,720
22,780
26,079
4,612
765
4,642
23,941
8,198
51,932
14,717
62,363
136)
44,208
2,730
31,669
765.871
2,572
768,443
746.924
-23-
continued..

Drng Safety Research Trnst
Note$ to the Finan¢ial Stat¢m¢nt$- ¢ontinMed
for the Year Ended 31 December 2025
AUDITORS, REMUNERATION
31112125
31112124
Fees payable to the charitys auditors for tbe audit of the charity's finan¢ial
statements
Audiiors, remuneraiTron for llon audit wo
16,090
2,220
11,720
TRUSTEES, REMUNERATION AND BENEFITS
Th¢ro were no trust¢es' remuneration OT Qther b¢nefits for the year et)ded 31 December 2025 nor for the year
¢nd¢d 31 Dec¢mber 2024.
Trustees, expenses
rrust¢es indemnity insurance payable during the year amounted to £8,160 (2024.. £7,844}.
Tn]stees expenses during the year aTrLount¢d ￿ £1,915 (2024.. £7L)
io.
srAFF COSTS
The ave¥age number of employees during the year was 26 (2024- 26}.
The number of ¢mploy¢¢s whose annu21 emoluments were £60,000 or more were..
2025
2024
£230,001- £31M).000
£II)0,001- £230,000
£70,001- £100,000
£60,001- £70,000
The Éotal remuneration iEJcluding pensions paid to key n￿llagernent personnel in the year was £265,460 (2024:
£266,912).
-24
Continued...

Drllg Safety Research Trust
Notes tts the Flnan¢i#l StAtemeDts- c•ntlDued
for the Year Ended 31 December 2025
ii.
TANGIBLE FIXED ASSETS
Fixtures
and
rittittgs
Freehold
property
Plant and
acbinery
Computer
system
Totals
COST
At l JatLuary 2025
A(Idrti(>ns
Disposals
941,0(Kl
220,436
32,714
{92,437)
67.857
13.213
57,036
1286,329
45,927
{149,473)
157.0361
At 31 December 2025
941,000
160,713
81.070
1,182.783
DEPRECIATION
At l January 2025
Charge foi year
Eli￿1￿ated on dtsposal
525,500
18,780
177,706
16,621
189,866)
66,383
3.107
57.036
826,625
38,508
{146,902}
{57.036)
At 31 December 2025
544280
104,461
69,490
718231
NET BOOK VALUE
At 31 December 2025
396.720
56,252
11,580
464.552
At 31 December 2024
415,500
42,730
1,474
459,704
The freehold property was last rev￿U¢d otj 20 December 1999 by M¢ssr5 Danie115 HaTison, Chartered
Surveyors, on the basis of open market value for currettt use. The freehold land and building5 valualiot) not
been updated since 1999. Und¢T the transitional relief provisions ullder FRS 102, this value has been treated as
the deemed cost in thes¢ finan¢ial statemellts.The estimated market va]ut per the charity as at the balan¢¢
sheet date, is in excess of £4 million.
Comparable historical cost for the land and buildings included at valuation..
2025
2024
Cost
A¢¢llmulated Depreciation
At year end
1,487,614
544 280
943 334
1,487.614
525 500
All other tangibl¢ fIxed assets are ￿ated at historical cost less ￿¢uMulated depreciatioTr.
-25-
continlle(L..

Drug Safrfy R¢sear¢h Trust
Notes to the FSrt#nclal St•tements- continued
for the Year Ended 31 DeCe￿ber 2025
12.
FIXED ASSET INTrTSTMENTS
Listed
Investments
MARKET VALUE
At l January 2025
Additions
Disposals
Reyaluatious
4,311,066
199,866
151Y),0001
209,474
At 31 Decetnbei 2025
4,220,406
NET BOOKVALUE
At 31 Decernber 2025
4,220,406
At 31 Decernber 2024
4,311,066
lThvestm¢nis were fomierly v&lued by ihe Investtnent Fund Managers. Investec Wealth and Investment Limited.
but then transferred to Rathbones UK mid year.
The asset allocation. including geographical location, of the ￿rtfoliO is set Ollt below..
2025
2024
UK fjxed income
Overseas fixed income
UK equities
Overseas equities
Property
Alternative$
C&sh
538,206
167,025
1,348,655
1,544,116
151,104
422,319
48,981
630,462
375,520
781,784
1.953.645
57,575
443,574
68,506
Total
4.220.406
4.311.066
Cost or valuation ￿ 31 December 2025 is represented by:
Listed
investments
Valuatiort in 2025
4,220,406
Net additions at ¢ost represent investm¢llt income Teinvested at souw¢ in the Televani fvnds held.
Investn￿ntS were valued by the Investment Fund Managers, Rathbon¢s UK, as at 31 December 2025.
-26-
continued...

Drug Safety Re5earth Trll5t
Note5 to the Fiti#n¢ial Statements- contlnued
for the Year Ellded 31 December 2025
13.
DEBTORS: AMOUNfs FALLING DUE WITHIN ONE YEAR
31112125
31112124
Trade debtors
Other debtors
Prepayments and acerned income
262,099
23,665
37,853
228,028
80,000
192,372
323,617
5Th),400
14.
CREDITORS: AMOUNtS FALLING DUE W￿H1￿ ONE YEAR
31112125
31￿￿24
Trade Creditors
Taxation and social security
Other Creditors
4,751
48,447
21.108
15.491
57,261
8,425
74,306
81,177
Is.
MOVEMENT IN FUNDS
Net
movement
in funds
At
311J2125
At 111125
Unrestrlcted funds
Ullrestticted Fund
6.866,214
{763,790)
6,102,424
Restricted fund$
Restricted Fund
415.500
118,780)
396,720
TOTAL FUNDS
7,281,714
{782,570)
6.499,144
Net movement in furtds, inclu(kd in the above are as follows..
Ineomlng
Tesollrces
Resources
expended
Gains and
losses
Movetnent
in funds
UDrestri¢ted fund$
Uwestricted Fund
1250,927
(2,224.191)
209,474
1763,790)
Restrlcted funds
Restricted Fund
(18,780)
118,780)
TOTAL FUNDS
1250,927
12242,971)
209.474
{782,570}
-27-
continued...

Drug Safety Research Trn5t
Detail¢d Statement of Fin#rtelal Activities
for the Year Ended 31 December 2025
31112125
31112124
INCOME AND ENDOWMENTS
Don8tloD$ and legacies
Donations
958,187
704,584
Investment Income
Gain on disposal of tnve5tment
Listed income
Interest ￿ceiVed
113.084
92,335
51,656
41.849
66.907
126.043
257.075
234,799
Otber income
Other income
35.665
233,762
Total Enco￿1￿% resources
1,250.927
1.173.145
EXPENDITURE
Investment managemeTht eosts
Fund manager ¢osts
24,341
24.633
Charitable aetlTr4ties
Wages- direct
Gencral Practiiioner costs
Other direci costs
.121.445
49,625
279,117
1,141,466
109,683
455,695
1,450,187
1,706,844
Support eosts
Ffnan¢e
Loss on sale of tangible fixed assets
2,572
Governance eosts
Wages
Social sea]rity
Pensions
Auditors, remuneratiot)
AudiÈors' remuneration for non audit work
Rates and water
Insurance
Light and heat
Telq)hont and fax
pps
Sundries
Repair5 and maitttenance
Carried forward
181,354
159,023
105,712
16,090
2.220
12.537
24.366
29.605
2.045
1,496
11,152
29.859
575.459
178.021
150.351
97,095
11,720
11,137
22,780
26,079
4.6L2
765
4,642
23,941
531,143
This page does not fom] part of the Statutory financial stattmcnts
-30-

Drug Safety Research Trust
Det•lled StatemeDt of Financial Activities
for the Year Ellded 31 December 2025
31112125
31112124
>vernaDce costs
Brought forward
Siaff medical cosÉs
Motor and trav¢1 exp¢ns¢s
Computcr costs
Subscriptions
Bank charges
Marketing eosts
Equipmcnt hire
D¢pT¢ciation of tall￿￿1¢ fixed #￿ets
575.459
5,642
49,140
16,954
47.418
824
30.074
1.852
38.508
531,143
8,198
51,932
14,717
62,363
{36}
44.208
2.730
31.669
765,871
746,924
Total r¢$our¢es expended
2.242,971
2,478,401
Net expenditllTe before gains Ios8es
1992.(H4) {1.305256)
Netlosses on Investments
Net gains I losses on ittvestments
209,474
113,703
Net expenditure
{782,570} (1,191,553)
ThÈs page does t)ot fomi part of the Sta￿tOry financial statements
-31-